Systemic Adeno-Associated Virus-Mediated Gene Therapy Prevents the Multiorgan Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion.

TitleSystemic Adeno-Associated Virus-Mediated Gene Therapy Prevents the Multiorgan Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion.
Publication TypeJournal Article
Year of Publication2020
AuthorsMatsumura Y, Li N, Alwaseem H, Pagovich OE, Crystal RG, Greenblatt MB, Stiles KM
JournalHum Gene Ther
Volume31
Issue3-4
Pagination163-182
Date Published2020 02
ISSN1557-7422
KeywordsAlcoholism, Aldehyde Dehydrogenase, Mitochondrial, Animals, Behavior, Animal, Biomarkers, Bone and Bones, Cell Line, Dependovirus, Disease Models, Animal, DNA Adducts, DNA Damage, Esophagus, Gene Expression, Gene Transfer Techniques, Genetic Therapy, Genetic Vectors, Humans, Liver, Male, Mice, Mice, Knockout, Phenotype, Transduction, Genetic, Transgenes, Treatment Outcome
Abstract

Aldehyde dehydrogenase type 2 (ALDH2), a key enzyme in ethanol metabolism, processes toxic acetaldehyde to nontoxic acetate. ALDH2 deficiency affects 8% of the world population and 35-45% of East Asians. The allele common genetic variant has a glutamic acid-to-lysine substitution at position 487 (E487K) that reduces the oxidizing ability of the enzyme resulting in systemic accumulation of acetaldehyde with ethanol ingestion. With chronic ethanol ingestion, mutations in ALDH2 are associated with a variety of hematological, neurological, and dermatological abnormalities, and an increased risk for esophageal cancer and osteoporosis. Based on our prior studies demonstrating that a one-time administration of an adeno-associated virus (AAV) serotype rh.10 gene transfer vector expressing the human cDNA (AAVrh.10hALDH2) prevents the acute effects of ethanol administration (the "Asian flush syndrome"), we hypothesized that AAVrh.10hALDH2 would also prevent the chronic disorders associated with ALDH2 deficiency and chronic ethanol ingestion. To assess this hypothesis, AAVrh.10hALDH2 (10 genome copies) was administered intravenously to two models of ALDH2 deficiency, knockout homozygous () and knockin homozygous () mice ( = 10 per group). Four weeks after vector administration, mice were given drinking water with 10-15% ethanol for 12 weeks. Strikingly, compared with nonethanol drinking littermates, AAVrh.10hALDH2 administration prevented chronic ethanol-induced serum acetaldehyde accumulation and elevated liver malondialdehyde levels, loss of body weight, reduced hemoglobin levels, reduced performance in locomotor activity tests, accumulation of esophageal DNA damage and DNA adducts, and development of osteopenia. AAVrh.10hALDH2 should be considered as a preventative therapy for the increased risk of chronic disorders associated with ALDH2 deficiency and chronic alcohol exposure.

DOI10.1089/hum.2019.268
Alternate JournalHum Gene Ther
PubMed ID31801381
PubMed Central IDPMC7047123
Grant ListR41 AA027739 / AA / NIAAA NIH HHS / United States
DP5 OD021351 / OD / NIH HHS / United States
Related Faculty: 
Matthew B. Greenblatt, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700